|Datasheet||Specific References||Reviews||Related Products||Protocols|
|Recombinant Cynomolgus CD153 / CD30L / TNFSF8 protein (Catalog#90091-C07H)|
|0.2 μm filtered solution in PBS|
|Produced in rabbits immunized with purified, recombinant Cynomolgus CD153 / CD30L / TNFSF8 (rh CD153 / CD30L / TNFSF8 ; Catalog#90091-C07H; G7P2F1; Gln63-Asp234). CD153 / CD30L / TNFSF8 specific IgG was purified by Cynomolgus CD153 / CD30L / TNFSF8 affinity chromatography.|
|Cynomolgus CD153 / CD30L / TNFSF8|
ELISA: 0.1-0.2 μg/mL
This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Cynomolgus CD153 / CD30L / TNFSF8 . The detection limit for Cynomolgus CD153 / CD30L / TNFSF8 is < 0.039 ng/well.
|This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.|
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
CD30 ligand (CD30L), also known as CD153 and TNFSF8, is a membrane-associated glycoprotein belonging to the TNF superfamily and TNFR superfamily, and is a specific ligand for CD30/TNFRSF8 originally described as a cell surface antigen and a marker for Hodgkin lymphoma and related hematologic malignancies. CD30L is a type-II membrane glycoprotein expressed on activated T cells, stimulated monocyte-macrophages, granulocytes, eosinophils, and some Burkitt-like lymphoma cell lines. CD30L is capable of transducing signals through CD30 on different CD30+ lymphoma cell lines, and mediates pleiotropic biologic effects including cell proliferation, activation, differentiation, as well as cell death by apoptosis. CD30-CD30 ligand interaction has been suggested to have a pathophysiologic role in malignant lymphomas, particularly Hodgkin disease, large cell anaplastic lymphomas and Burkitt lymphomas, and is also involved in activation and functioning of the T cell-dependent immune response. Thus, CD153 and its receptor CD30 are regarded as therapeutic targets in hematologic malignancies, autoimmune and inflammatory diseases.